Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old
NCT07187375
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
6
Enrollment
INDUSTRY
Sponsor class
Conditions
Congenital Adrenal Hyperplasia
Interventions
DRUG:
Crinecerfont
Sponsor
Neurocrine Biosciences